We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > ZYNLONTA

News List

Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics contractpharma
May 26, 2021
Avid Bioservices Inc., a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing development and manufacturing services to biotechnology and pharmaceutical companies, will serve as ...
FDA Approves ADC Therapeutics' Zynlonta contractpharma
May 08, 2021
ADC collaborated with CDMO Sterling Pharma Solutions to develop the cancer drug.
ADC Therapeutics gets USFDA nod for ZYNLONTA to treat relapsed or refractory diffuse large B-cell lymphoma expresspharma
April 26, 2021
First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).